Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2015-11-12 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about the company presenting at a healthcare conference. The document is short (2291 characters) and does not contain financial statements or detailed financial data. It is primarily an announcement of an event (presentation at a conference) rather than a full report or detailed financial disclosure. Form 6-K filings typically serve as periodic reports for foreign private issuers to disclose material information. Given the content and length, this filing best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes Form 6-K submissions.
2015-11-12 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release reporting third quarter 2015 results and condensed interim unaudited financial information for the nine and three months ended September 30, 2015. Form 6-K is used to report interim financial information and other material information by foreign private issuers. The content includes interim financial data, indicating it is an Interim / Quarterly Report rather than just an announcement or certification. The document length is under 5,000 characters but contains substantive financial data, so it is not merely a report publication announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2015-11-09 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing submitted to the SEC by a foreign private issuer, RedHill Biopharma Ltd. It contains a press release announcing the first European marketing approval of a product (RIZAPORT) and references incorporation by reference into registration statements. The document is short (2367 characters) and primarily serves as a regulatory announcement of a press release rather than a detailed financial report or earnings release. Form 6-K filings are typically used for current reports by foreign private issuers and often contain press releases or other material information. This does not fit the definitions of Annual Report, Earnings Release, or other detailed financial filings. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement and current report.
2015-11-09 English
FORM S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes details about the stock option plan, registration fee calculation, incorporation by reference of other filings, and indemnification provisions for directors and officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is a full registration statement, not a brief announcement or certification.
2015-10-29 English
FORM 6-K
AGM Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Redhill Biopharma Ltd., reporting resolutions approved at the Annual General Meeting (AGM) held on October 29, 2015. The resolutions include appointment of auditors and re-election of board members. The content focuses on shareholder meeting outcomes and board appointments, which aligns with announcements related to board/management changes and AGM results. However, since it reports on resolutions passed at the AGM, it fits best under AGM Information (AGM-R), which covers presentations and materials shared during the AGM. The document is relatively short (2254 characters) and does not contain detailed financial data or full reports, so it is not an Annual Report or Audit Report. Therefore, the classification is AGM Information (AGM-R).
2015-10-29 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about hosting a third quarter 2015 financial results conference call. The document length is 2300 characters, which is relatively short and mainly serves as an announcement rather than containing detailed financial data or the full report itself. The content is consistent with a regulatory filing that provides an update or announcement rather than the full financial report or transcript. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and not as a full earnings release or call transcript.
2015-10-29 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.